Suryaa Now Business News Desk: Switzerland-based biotechnology firm Windward Bio Group, supported by life sciences investment firm Novo Holdings, has successfully entered the United States stock market. The company’s shares began trading on the Nasdaq Global Market with gains, bringing its market valuation to approximately $1.07 billion.
Windward Bio, headquartered in Basel, issued its shares at $17 each as part of its initial public offering, falling within the set range of $16 to $18. Through this public offering, the company raised approximately $175 million. The company is trading on the Nasdaq under the ticker symbol "WWB."
The company stated that it intends to use the funds for the development of advanced antibody drugs for chronic respiratory and skin diseases, as well as for conducting clinical trials. Additionally, French pharmaceutical company Sanofi has committed to a $50 million investment through a private placement. The IPO has drawn significant attention due to the backing of major firms including Novo Holdings, OrbiMed, and Blue Owl.